Crinetics Pharmaceuticals will update on PALSONIFY™ commercialization and atumelnant trial results via conference call on January 5, 2026.
Quiver AI Summary
Crinetics Pharmaceuticals, Inc. announced a conference call and webcast scheduled for January 5, 2026, at 8:30 a.m. ET to share updates on the commercialization of PALSONIFY™ (paltusotine) and to announce topline results from a Phase 2 trial of atumelnant for congenital adrenal hyperplasia. The call will include a live question-and-answer session following the main presentation. PALSONIFY™ is the first FDA-approved oral treatment for adults with acromegaly who had inadequate responses to surgery, and it is also being developed for carcinoid syndrome related to neuroendocrine tumors. Crinetics has a robust pipeline of over ten programs aimed at various endocrine diseases, including atumelnant for congenital adrenal hyperplasia and CRN09682 targeting SST2-expressing tumors. Investors and media contacts are provided for further inquiries.
Potential Positives
- Crinetics Pharmaceuticals is providing an update on PALSONIFY™ commercialization, highlighting their commitment to advancing their lead product in the market.
- The announcement includes the disclosure of topline results from the fourth cohort of the Phase 2 trial of atumelnant, which signifies progress in their clinical development pipeline.
- The company showcases its dedication to addressing serious health conditions, particularly in endocrine diseases, reinforcing its mission-driven approach to patient care.
Potential Negatives
- Conference call is focused on topline results from a clinical trial, which may indicate uncertainty about the drug's efficacy and the company's future prospects.
- Dependence on the success of a single lead product (PALSONIFY™) for growth could pose financial risks if sales do not meet expectations.
- Failure or delays in ongoing clinical trials could adversely affect investor confidence and stock performance.
FAQ
What is the date and time of the Crinetics conference call?
The conference call will take place on January 5, 2026, at 8:30 a.m. ET.
How can I access the live webcast for the conference call?
You can access the live audio-only webcast by clicking on the provided link or visiting Crinetics' website.
What topics will be discussed during the conference call?
The call will provide updates on PALSONIFY™ commercialization and topline results from the atumelnant Phase 2 trial.
What is PALSONIFY™ and its significance?
PALSONIFY™ (paltusotine) is the first oral treatment approved by the FDA for adults with acromegaly not responding to surgery.
Who can I contact for investor relations at Crinetics?
You can contact Gayathri Diwakar, Head of Investor Relations, at [email protected] or (858) 345-6340.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRNX Insider Trading Activity
$CRNX insiders have traded $CRNX stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $CRNX stock by insiders over the last 6 months:
- DANA PIZZUTI (Chief Med and Dev Officer) has made 0 purchases and 7 sales selling 56,492 shares for an estimated $1,910,298.
- MATTHEW K FUST sold 16,000 shares for an estimated $716,000
- RICHARD SCOTT STRUTHERS (President & CEO) sold 4,000 shares for an estimated $180,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CRNX Hedge Fund Activity
We have seen 124 institutional investors add shares of $CRNX stock to their portfolio, and 106 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 2,574,683 shares (+44.3%) to their portfolio in Q3 2025, for an estimated $107,235,546
- FARALLON CAPITAL MANAGEMENT LLC added 1,124,000 shares (+24.2%) to their portfolio in Q3 2025, for an estimated $46,814,600
- STATE STREET CORP removed 1,016,599 shares (-31.5%) from their portfolio in Q3 2025, for an estimated $42,341,348
- JPMORGAN CHASE & CO added 926,765 shares (+279.2%) to their portfolio in Q3 2025, for an estimated $38,599,762
- VESTAL POINT CAPITAL, LP removed 750,000 shares (-50.0%) from their portfolio in Q3 2025, for an estimated $31,237,500
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 655,588 shares (-91.5%) from their portfolio in Q3 2025, for an estimated $27,305,240
- FRANKLIN RESOURCES INC removed 628,738 shares (-96.9%) from their portfolio in Q3 2025, for an estimated $26,186,937
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CRNX Analyst Ratings
Wall Street analysts have issued reports on $CRNX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 11/07/2025
- Oppenheimer issued a "Outperform" rating on 09/30/2025
- Leerink Partners issued a "Outperform" rating on 09/29/2025
- JMP Securities issued a "Market Outperform" rating on 09/26/2025
- Baird issued a "Outperform" rating on 09/26/2025
- JP Morgan issued a "Overweight" rating on 09/24/2025
To track analyst ratings and price targets for $CRNX, check out Quiver Quantitative's $CRNX forecast page.
$CRNX Price Targets
Multiple analysts have issued price targets for $CRNX recently. We have seen 8 analysts offer price targets for $CRNX in the last 6 months, with a median target of $82.0.
Here are some recent targets:
- Jonathan Wolleben from Citizens set a target price of $108.0 on 11/07/2025
- Leland Gershell from Oppenheimer set a target price of $87.0 on 09/30/2025
- Joseph Schwartz from Leerink Partners set a target price of $88.0 on 09/29/2025
- Jeffrey Hung from Morgan Stanley set a target price of $77.0 on 09/29/2025
- Jonathan Wolleben from JMP Securities set a target price of $143.0 on 09/26/2025
- Brian Skorney from Baird set a target price of $62.0 on 09/26/2025
- Richard Law from Goldman Sachs set a target price of $40.0 on 09/26/2025
Full Release
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia.
Conference Call and Webcast Details
Management will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast,
click here
. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at
www.crinetics.com/events
. To participate, please dial 1-833-470-1428 (domestic) or 1-646-844-6383 (international) and refer to Access Code 640078.
ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
[email protected]
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
[email protected]
(858) 345-6075
